Modern cancer care for the next billion people
Hedera Dx enables health systems, patients and drug development programs to easily adopt advanced molecular testing and real-world evidence (RWE) capabilities.
Advanced NGS solutions provide better therapy options for more patients
Advanced tumor profiling solutions are required to provide the right and most advanced cancer therapies. In addition to the traditional tissue biopsy, liquid biopsy testing is also needed to cover for patients with failed or unfeasible FFPE testing.
Hedera Dx provides hospital in-house laboratories a full suite of NGS genomic profiling solutions, covering FFPE testing, ctDNA testing and RNA only testing.
Liquid biopsy can be used alone or in combination with tissue biopsy across the entire patient journey
How it works
A radically streamlined biopsy process
Our solution integrates swiftly into existing settings of molecular pathology laboratories with unrivaled simplicity.
Blood draw
When a physician decides to do a liquid biopsy test to find the best treatment option for the patient, a simple blood draw is ordered.
Sequencing
After the patient’s blood sample is sent to the hospital lab, ctDNA is extracted from the plasma and Next Generation Sequencing (NGS) is performed with the Hedera Dx assay.
Clinical report
Using our software, a report is generated that provides options of regulatory-approved therapies to the patient’s tumor ctDNA sequence.
Therapy options
The physician discusses the report results within his institution to ultimately determine the best path forward for treatment in alignment with the patient’s preferences.
Growing Body of Real-World Clinical Evidence for In-House Tumor Profiling
EMPATHY NSCLC
Real-world utility and clinical validation study (ClinicalTrials.gov identifier: NCT07096258)
EMPATHY NSCLC is the first European, Prospective, Multicenter Clinical Validation study for the in-house liquid biopsy testing, enabling Real-World assessment of current NGS-based liquid biopsies practices in hospital laboratories.
April 14, 2026
Conference Lunch Symposium: From Innovation to Clinical Practice Quality, Robustness, and Readiness of Liquid Biopsy
April 14, 2026
Conference Lunch Symposium: From Innovation to Clinical Practice Quality, Robustness, and Readiness of Liquid Biopsy
- Malapelle, U et al. Liquid Biopsy for Biomarker Testing in Non-Small Cell Lung Cancer: A European Perspective. J. Mol. Pathol. 2021, 2, 255-273. https://www.mdpi.com/2673-5261/2/3/22
- Pascual, J et al. “ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group.” Annals of oncology : official journal of the European Society for Medical Oncology vol. 33,8 (2022): 750-768. doi:10.1016/j.annonc.2022.05.520